Kimelman & Baird’s Trinity Biotech TRIB Stock Holding History

Kimelman & Baird’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-21,473	Closed	-$1.42M	–	123
2016 Q3	$1.42M	Sell	21,473 -120	-0.6%	-$7.47K	0.25%	55
2016 Q2	$1.22M	Sell	21,593 -280	-1%	-$15.8K	0.22%	55
2016 Q1	$1.27M	Buy	21,873 +135	+0.6%	+$7.17K	0.24%	56
2015 Q4	$1.28M	Buy	+21,738	New	+$1.28M	0.24%	61
2015 Q2	$3.82M	Buy	42,297 +6,569	+18%	+$569K	0.65%	45
2015 Q1	$3.44M	Buy	35,728 +8,750	+32%	+$809K	0.63%	47
2014 Q4	$2.36M	Sell	26,978 -8,880	-25%	-$765K	0.43%	51
2014 Q3	$3.28M	Sell	35,858 -760	-2%	-$82.3K	0.62%	46
2014 Q2	$4.22M	Buy	36,618 +1,740	+5%	+$206K	0.74%	42
2014 Q1	$4.23M	Buy	34,878 +22,356	+179%	+$2.93M	0.79%	37
2013 Q4	$1.57M	Buy	+12,522	New	+$1.5M	0.3%	61

Other funds holding TRIB

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

SCM

Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Kimelman & Baird's TRIB Position: Q4 2016 in Review

Kimelman & Baird sold out of Trinity Biotech (TRIB) in Q4 2016, closing a stake of 21,473 shares — an estimated $1.42M sold.

Kimelman & Baird first reported a position in TRIB in Q4 2013 and held it in 11 quarters. The position peaked at $4.23M in Q1 2014. 71 funds tracked by Wall St. Rank hold TRIB as of Q4 2016.

Kimelman & Baird reported no remaining Trinity Biotech position as of Q4 2016 after selling out during the quarter.
Kimelman & Baird sold 21,473 Trinity Biotech shares in Q4 2016, an estimated $1.42M.
Kimelman & Baird first reported a position in Trinity Biotech in Q4 2013 and held it in 11 quarters.
Kimelman & Baird's Trinity Biotech position peaked at $4.23M in Q1 2014.
71 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2016.

Based on Kimelman & Baird's 13F filing for Q4 2016, filed 10 Apr 2017.